Simplexa® C. difficile Universal Direct Kit
In vitro qualitative assays for the direct detection of C. difficile
Each kit provides a throughput choice. The Universal Direct Kit expands to 96 samples.
Powered by Bioz
Disease state
According to the CDC, Clostridium difficile is now the most common microbial healthcare associated infection (HAI), with annual healthcare costs exceeding $4.8 billion. Approximately 15,000 deaths are attributable to C. difficile infection each year in the US.
C. difficile is a common but expensive to treat infection
The Value of Simplexa® C. difficile Universal Direct Kit
Empower clinicians to quickly treat and isolate patients.
Rapid results and high-throughput
Simplexa® C. difficile Universal Direct assay for up to 94 patient samples per run with results in about 1 hour.
Delivers diagnostic confidence
Greater than 99% positive agreement.
How the Simplexa® C. difficile Universal Direct Kit works
Sample-to-answer
Simple sample prepartion with no extaction step required.
One target, two consumables
Select the kit that fits your workflow needs. The 96-well Universal Disc allows for higher volume, batched runs.
To be used on the LIAISON® MDX Instrument
The LIAISON® MDX is an innovative and powerful real-time PCR instrument with two consumable disc options: the 8-well Direct Amplification Disc and the 96-well Universal Disc for higher volume testing.
Supported by an expanding menu of molecular assays, the system provides easy-to-understand results with the ability to check amplification curves after a run. All of this in a compact footprint measuring only 12″ by 8″ by 12″ so that it can fit into laboratories of any size.
Simplexa® C. difficile Universal Direct Kit ordering info
Part Name |
Kit Size |
Registration Status |
Part Number |
|---|---|---|---|
|
Simplexa® C. difficile Universal Direct Kit |
100 |
IVD | MOL2975 |